Related Experiment Videos
Cutaneous toxicity associated with high-dose cytosine arabinoside
1College of Nursing, University of Arkansas for Medical Sciences, Little Rock.
Oncology Nursing Forum
|September 1, 1992
Summary
High-dose cytosine arabinoside (HDAC) can cause significant skin toxicity in leukemia patients, ranging from redness to painful blistering. Further research is needed to develop effective interventions for managing this common side effect.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- High-dose cytosine arabinoside (HDAC) is a critical chemotherapy agent for treating acute and chronic leukemia and non-Hodgkin's lymphoma.
- Cutaneous toxicity is a significant adverse event associated with HDAC therapy, impacting patient comfort and daily activities.
Observation:
- The incidence of skin toxicity from HDAC ranges widely from 3% to 72%.
- Manifestations include erythema, painful swelling, bullae formation, and desquamation, with unclear etiology.
- Toxicity severity correlates with the number of consecutive HDAC doses administered.
Findings:
- Current literature reveals minimal scientifically examined interventions for preventing or treating HDAC-induced cutaneous toxicity.
- The terminology used to describe skin toxicity varies, complicating consistent reporting and research.
Implications:
- Nurses face challenges in managing HDAC-related skin complications, requiring exploration of effective interventions.
- Minimizing toxicity and addressing its impact on patients' quality of life is a key nursing priority.
- Further investigation into the pathophysiology and treatment of cutaneous toxicity is essential for improving patient care.